Adverse events202

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 202

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Intraocular pressure increased	Investigations	E10030 + Bevacizumab or Aflibercept	22	322	46
other	Intraocular pressure increased	Investigations	Sham + Bevacizumab or Aflibercept	20	320	35
other	Conjunctival haemorrhage	Eye disorders	E10030 + Bevacizumab or Aflibercept	39	322	85
other	Conjunctival haemorrhage	Eye disorders	Sham + Bevacizumab or Aflibercept	31	320	48
other	Punctate keratitis	Eye disorders	E10030 + Bevacizumab or Aflibercept	21	322	34
other	Punctate keratitis	Eye disorders	Sham + Bevacizumab or Aflibercept	14	320	39
other	Eye pain	Eye disorders	E10030 + Bevacizumab or Aflibercept	18	322	26
other	Eye pain	Eye disorders	Sham + Bevacizumab or Aflibercept	21	320	35
other	Vitreous detachment	Eye disorders	E10030 + Bevacizumab or Aflibercept	20	322	21
other	Vitreous detachment	Eye disorders	Sham + Bevacizumab or Aflibercept	19	320	23
other	Neovascular age-related macular degeneration	Eye disorders	E10030 + Bevacizumab or Aflibercept	16	322	16
other	Neovascular age-related macular degeneration	Eye disorders	Sham + Bevacizumab or Aflibercept	19	320	19
other	Nasopharyngitis	Infections and infestations	E10030 + Bevacizumab or Aflibercept	14	322	15
other	Nasopharyngitis	Infections and infestations	Sham + Bevacizumab or Aflibercept	17	320	18
serious	Anaemia	Blood and lymphatic system disorders	E10030 + Bevacizumab or Aflibercept	3	322	3
serious	Anaemia	Blood and lymphatic system disorders	Sham + Bevacizumab or Aflibercept	0	320	0
serious	Haemorrhagic anaemia	Blood and lymphatic system disorders	E10030 + Bevacizumab or Aflibercept	1	322	1
serious	Haemorrhagic anaemia	Blood and lymphatic system disorders	Sham + Bevacizumab or Aflibercept	0	320	0
serious	Thrombocytopenia	Blood and lymphatic system disorders	E10030 + Bevacizumab or Aflibercept	1	322	1
serious	Thrombocytopenia	Blood and lymphatic system disorders	Sham + Bevacizumab or Aflibercept	0	320	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01940887/events

API reference For AI assistants

Adverse events202

Sources 3

Read this list from software.